Equities

Redsense Medical AB (publ)

Redsense Medical AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)7.44
  • Today's Change0.14 / 1.92%
  • Shares traded553.00
  • 1 Year change-17.15%
  • Beta--
Data delayed at least 15 minutes, as of Jul 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Redsense Medical AB (publ) is a Sweden-based company, which is primarily involved in the healthcare industry. The Company is active within the field of hemodialysis. It operates as a manufacturer of blood loss detection device that is designed to alarm on blood leakage from the venous blood access. The Company's Redsense system consists of an alarm unit, an extension fiber and a non invasive sensor patch. When the sensor patch is placed over the blood access, it detects any blood coming in contact with the sensor. This can occur if the needle is accidentally dislodged or if blood is leaking during dialysis. The Redsense system is designed to alarm when blood reaches the sensor, so the dialysis caregiver or observing person at home, can apply appropriate action when a venous needle dislodges.

  • Revenue in SEK (TTM)19.85m
  • Net income in SEK-7.57m
  • Incorporated2003
  • Employees5.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BBS-Bioactive Bone Substitutes Oyj0.00-40.70m77.31m----1.23-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
SciBase Holding AB (publ)24.15m-55.54m77.89m26.00--2.04--3.22-0.5255-0.52550.22370.24570.30040.78634.33894,592.60-69.07-68.63-90.03-87.7769.2861.28-229.94-300.201.78--0.00--29.9327.50-28.75--5.15--
Bio Vitos Pharma AB2.61m-12.87m81.74m1.00--2.75--31.28-0.1738-0.17380.02160.10120.09780.05645.492,613,400.00-48.17-31.11-49.96-32.9298.14---492.58-1,026.765.48--0.00--126.97--13.64------
Scandinavian Real Heart AB0.00-71.66m82.35m11.00--0.5501-----0.4709-0.47090.000.51440.00----0.00-67.22-24.27-78.30-26.81--832.41---6,070.11---701.980.0945---100.00---385.97---25.76--
PMD Device Solutions AB39.68m-35.45m94.24m1.00------2.37-2.06-2.064.14-5.151.58--30.16---141.30------78.66---89.34--0.0373-1.81----------------
ScandiDos AB60.43m-14.65m96.92m34.00--1.75--1.60-0.3211-0.32111.320.9710.78530.55526.07---19.03-12.60-33.80-21.9378.6982.13-24.24-15.370.9148-11.58-----1.824.36-60.62---19.29--
Clinical Laserthermia Systems AB10.83m-70.90m98.44m7.00--0.9836--9.09-14.73-14.731.935.790.217312.584.86---144.45-123.49-259.50-312.95-392.44-1,084.16-664.90-1,625.032.06-30.970.0094--31.9935.55-12.92--18.26--
Ortivus AB78.15m-20.63m103.03m42.00--6.38--1.32-0.4655-0.46551.760.35291.003.364.761,953,650.00-26.44-2.41-51.70-4.6333.8842.46-26.39-1.770.5256--0.4544---19.5510.00-409.66--67.43--
Luxbright AB952.90k-25.38m105.17m10.00--2.64--110.37-0.2752-0.27520.01030.36530.0265--1.9995,290.00-70.61-61.39-81.90-70.36-947.28-559.15-2,662.94-2,459.34---1,722.290.0061--73.46---20.07------
Observe Medical ASA27.31m-58.99m107.27m12.00--0.6928--3.93-1.05-1.050.48490.60630.11912.497.122,328,500.00-25.72-32.60-35.90-49.8033.2432.83-216.03-256.250.334-6.010.3204--43.14204.81-18.82--32.69--
Dignitana AB85.74m-18.48m117.59m28.00--38.00--1.37-0.2487-0.24871.150.03841.663.3514.613,175,519.00-35.81-42.21-97.80-68.9169.1166.09-21.55-57.290.3234-8.840.8571--17.9020.5922.52---15.31--
Toleranzia AB0.00-6.30m117.85m7.00--0.7716-----0.0405-0.04050.000.7750.00----0.00-4.50-7.45-4.65-7.78------------0.00------11.79--63.90--
Redsense Medical AB (publ)19.85m-7.57m120.05m5.00--5.15--6.05-0.5389-0.53891.411.420.72614.515.023,970,800.00-27.67-18.66-31.75-20.9950.1169.02-38.11-46.282.21--0.00--74.1128.9448.47---23.62--
Nanexa AB28.91m-70.62m126.74m19.00--1.36--4.38-0.8143-0.81430.32520.68540.2069-33.452.261,521,474.00-50.54-40.77-66.82-48.77124.7077.27-244.28-532.262.14--0.0193--925.42147.00-30.44--39.10--
Episurf Medical AB11.00m-92.10m135.73m25.00--1.12--12.34-0.266-0.2660.03180.18610.0852--5.24392,857.20-71.42-47.46-81.48-52.01-----838.18-1,019.292.54--0.068--53.6219.78-22.64---0.4158--
Iconovo AB6.10m-39.03m141.67m29.00--1.15--23.24-3.01-3.010.45267.710.0434--1.04210,251.40-27.76-25.43-31.28-28.24323.68134.57-640.15-215.16----0.0669---58.65-9.884.71--34.70--
Data as of Jul 25 2024. Currency figures normalised to Redsense Medical AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

10.60%Per cent of shares held by top holders
HolderShares% Held
Discover Capital GmbHas of 31 Dec 2023750.00k4.56%
Swedbank Robur Fonder ABas of 28 Jun 2024539.85k3.28%
Aktia Bank Plc (Investment Management)as of 28 Jun 2024310.00k1.89%
Schroder Investment Management Ltd.as of 31 Dec 2023141.14k0.86%
AIFM Capital ABas of 31 Dec 20211.71k0.01%
Evli Fund Management Co. Ltd.as of 28 Jun 20241.00k0.01%
More ▼
Data from 31 Dec 2021 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.